The practices of some California insurers have recently come under attack in lawsuits brought by private litigants and in administrative actions brought by state regulators. The practice involves the rescission of health insurance policies due to misrepresentations made in the policy application form.
The rescission of a policy is a cancellation of coverage ab initio-retroactive back to inception. Premiums that have been paid are returned to the insured when the notice of rescission is given. Such a cancellation is a harsh measure in that it usually occurs after the insured has already incurred claims. Consequently, it is a seldom used practice-it is primarily reserved for extreme cases of misrepresentation. Moreover, it typically only affects insurance that is purchased on an individual basis, as compared with group health insurance.
Most states, by statute, provide some general rules that are to be followed when rescinding a policy based upon the insured's misrepresentation. First, the completed application must have been attached to the policy when it is provided to the insured. Second, the insured's misrepresentation must be material to the risk or to the event upon which benefits become due and payable. Third, the insurer must provide notice to the insured of the misrepresentation (and the decision to rescind) within a reasonable time of discovering the misrepresentation-typically 90 days.
PROOF OF INTENT
Requiring proof of intent to deceive is still a minority position among the states-meaning that the courts of most states do not require such a finding in order to justify a rescission. Proving the insured's intent often is a very difficult burden. The insurer will often have to rely strictly on circumstantial evidence-the existence of circumstances which indicate that the statements must have been known by the insured to be false, or that they are of such a character as clearly to prove a conscious misrepresentation by the insured.
The test for materiality is whether the policy would have been denied if the information had been revealed on the application. Thus, the question is whether the misrepresentation was relevant to a risk covered by a policy or whether the condition that existed actually contributed to an event under which policy benefits were paid. This analysis is based upon the facts that existed at the time of the issuance of the policy rather than at the time that the benefits were accessed by the insured.
The statutes and case law which establish the basis for a rescission impose a heavy burden of proof on the insurer. Another complicating factor is that the insurer faces this dilemma many months, perhaps years, after the application has been taken from the insured. To the extent possible, the insurer must take on the difficult task of gathering evidence and circumstances showing that the statements in the application were false, were known to be false, and were relied upon by the insurer in issuing the coverage.
This column is written for informational purposes only and should not be construed as legal advice.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More